Chang Hannah, Klein Jeffrey S, Norotsky Mitchell, Cooper Kumarasen
University of Vermont College of Medicine, Burlington, VT 05401, USA.
J Thorac Imaging. 2004 Jan;19(1):60-2. doi: 10.1097/00005382-200401000-00013.
Bacillus Calmette-Guerin (BCG) is well accepted as an intravesicular method of treatment of bladder cancer. Although well tolerated in the majority of patients, adverse local and systemic adverse effects of this therapy have been described. In particular, lung disease complicating intravesicular use of BCG has been reported, producing 5 recognized forms of chest disease: 1) allergic interstitial lung disease, 2) miliary infection, 3) empyema, 4) diffuse alveolar damage, and 5) localized consolidative or cavitary lung disease. We report an asymptomatic form of pulmonary disease complicating intravesical BCG therapy, that of pulmonary granulomas with mediastinal and hilar lymph node enlargement.
卡介苗（BCG）作为一种治疗膀胱癌的膀胱内给药方法已被广泛接受。尽管大多数患者对其耐受性良好，但这种治疗方法的局部和全身不良反应已有报道。特别是，已有报告称膀胱内使用卡介苗会并发肺部疾病，产生5种公认的胸部疾病形式：1）过敏性间质性肺病，2）粟粒性感染，3）脓胸，4）弥漫性肺泡损伤，5）局限性实变或空洞性肺病。我们报告了一种膀胱内卡介苗治疗并发的无症状肺部疾病形式，即伴有纵隔和肺门淋巴结肿大的肺部肉芽肿。
